Vidac Pharma

It is a big honor to be included in the same press Article in the economic press with Bayer and BioNTech SE.. but we are however not totally surprised as we are the only company which was able to develop new molecules reversing the Warburg effect. As a clinical stage company, we showed efficacy and extremely low side effects in two oncodermatolgy indications in Phase 2. This recognition gives us even more incentive to push the developments of our new molecules addressing solid tumors with the same mode of action. #cancer #biotech #oncology #science #vidacpharma https://lnkd.in/ePHSdJ7T

The U.S. Patent and Trademark Office has granted a patent that will give Vidac Pharma’s family of oncology drug candidates a broad protection. The patent is for the underlying mode of action for all Vidac’s drug candidates, which reverse the abnormal metabolism of cancer cells by unblocking the wrong anchoring of the hexokinase 2 enzyme (HK2) to the mitochondrial VDAC pores. “To the best of our knowledge, we are the only company in the world whose products reverse the supercharged metabolism of cancer cells – known as the Warburg effect - and we are now holding the exclusive patent to this extremely promising mode of action,” said Prof Max Herzberg, Chief Executive Officer of Vidac Pharma. To read more about Vidac’s science, click here: https://lnkd.in/eShX_zXX Vidac’s VDA-1102 is in Phase 2 clinical studies to treat advanced actinic keratosis and cutaneous T-cell lymphoma. Its other drug candidate, VDA-1275, has shown promising effects in preclinical studies, both directly against a variety of tumors in animal trials, and through powerful synergistic effects in combination with two widely used types of chemotherapy in human liver organoids. #cancer #biotech #oncology #science #vidacpharma

Vidac Pharma’s two cancer drug candidates could prove to be “groundbreaking”, investor website news.financial said, because of Vidac’s entirely new mode-of-action. Vidac therapies revert the turbo-charged metabolism of cancer cells back to normal. This slows down cell proliferation, restores programmed cell death, and breaks down the immuno-suppressant protective zone around tumors. “Demographic changes point to a long-term explosion in demand for new medications,” the website said in an update. This boded well for shares of innovative companies such as Vidac Pharma which have suffered from high interest rate levels in the past few years. news.financial also quoted the recent “Buy” rating for Vidac shares in a recent note from analysts at Sphene Capital. To read the note, click here: https://lnkd.in/d5yEStxk To read more about Vidac’s science, click here: https://lnkd.in/eShX_zXX To read the article in News Financial, click here: https://lnkd.in/ecZcZ7Tf #cancer #biotech #oncology #science #vidacpharma

Thank you The Big Idea CONNECTpreneur Community for this amazing opportunity. We are looking forward to presenting our company at the August virtual event this evening. Please make sure to register for this event.

Thank you Opus8, Inc. for this wonderful opportunity to introduce our company at the Virtual Event this evening. Please make sure to register. We will be almost at the end of the session. We are looking forward to e-meet you.

News that Vidac Pharma has made positive results from its cancer drug candidate VDA-1275 available online triggered research analysts at Germany’s Sphene Capital to highlight the company’s potential in a new note to investors this week. “We hereby confirm our “Buy” rating and our three-stage discounted cash flow entity model-based price target of €4.90 (base case scenario),” Sphene Capital GmbH said in a note. That scenario is based on the assumption that Vidac will secure market approval for its lead drug candidate, VDA-1102, for actinic keratosis, an early stage of skin cancer. The results showed a host of positive effects from VDA-1275. It reinstates the programmed death of cancer cells, halts rapid proliferation, reverses the abnormal metabolism of cancer cells, triggers an immunologic response of its own, shows strong synergistic effects with commonly used cancer treatments, and enhances survival. Vidac Pharma develops cancer drugs that prevent the wrong anchoring of the HK2 enzyme to the mitochondrial VDAC pores, without affecting its benign everyday functioning in the cellular metabolism, meaning the drugs have very few side effects. To read the Sphene report, click here https://lnkd.in/dzp26JsP To read our press release about VDA-1275, click here https://lnkd.in/dcfDDaCG. To read more about our science, click here https://lnkd.in/d2zGrtBn . hashtag #cancer #biotech #oncology #science #drugdevelopment #pharma #medicine

In February, Vidac announced promising results of a study with its VDA-1275 cancer drug candidate. Now, it has made the full results available online. VDA-1275 goes to the heart of cancer, reversing the abnormal (hyperglycolytic) metabolism that is a common characteristic of all cancer cells. The study was into multiple mouse cancer and human cellular organoid models of solid tumors, and showed that VDA-1275: • reinstates apoptosis (programmed cell death), • halts rapid proliferation of cancer cells, • reduces hyper-glycolytic metabolism typical of tumors • triggers an immunologic response • increases survival (in a murine colorectal cancer model) • demonstrates a synergistic effect in combination with widely used anti-cancer drugs (in a 3D organoid model of human liver cancer) Vidac Pharma develops cancer drugs that prevent the wrong anchoring of the HK2 enzyme to the mitochondrial VDAC pores, without affecting its benign everyday functioning in the cellular metabolism, meaning the drugs have very few side effects. For the full article, click here https://lnkd.in/dvDa2GAv For the press release please click here https://lnkd.in/dDGFH-gB

Vidac Pharma stood in the limelight when news.financial took a look at pioneering companies working to discover a new cure for cancer. “With around 20 million cancer diagnoses worldwide each year, innovative therapeutic approaches are urgently needed,” the website for investors said. Vidac is developing therapies that revert the turbo-charged metabolism of cancer cells back to normal. This slows down cell proliferation, restores programmed cell death, and breaks down the immuno-suppressant protective zone around tumors. To read more about our science, click here: https://lnkd.in/eShX_zXX To read the article in News Financial, click here: https://lnkd.in/eGhcw93r #cancer #biotech #onchology #science #vidacpharma

When Megan Thomas at Drug Discovery World set out to discover what lies ahead in cancer research, one of the companies she spoke to was Vidac Pharma. Chief Executive Officer Prof max herzberg explained how we are aiming to reverse the abnormal metabolism fueling malignant cells to treat cancer. Vidac Pharma is developing new drugs based on this principle, and has already shown some very promising results – in the laboratory as well as in patients. To read more about the science Vidac is using to develop its therapies, and our pipeline of candidate drugs, please visit our website at www.vidacpharma.com To read the article in Drug Discovery World, please click on this link: https://lnkd.in/gtSZijU9 #cancer #biotech #onchology #science #vidacpharma #dermatology

Research analysts at Germany’s Sphene Capital GmbH estimated that each Vidac Pharma share represents a value of €4.90, initiating coverage of the shares with a Buy rating. The valuation – which represents vast upside from where the stock is trading today – is based on the assumption that Vidac will obtain market approval for VDA-1102, its most advanced therapeutic candidate, for actinic keratosis. “If the market entry with VDA-1102 succeeds in 2027 as we expect, we assume that the company will achieve profitability ratios like comparable pharmaceutical companies in a very short time,” the analysts said their 75-page strong report. Other points making Vidac attractive were its two-product pipeline, being a pioneer in treating actinic keratosis with the toposteric effect, application across a wide range of tumors, a stable shareholder structure, and a clear undervaluation by the market. To read the full report, go to our website: https://lnkd.in/da-3wkFm #cancer #biotech #onchology #science #vidacpharma